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Abstract: Nosocomial diseases represent a huge health and economic burden. A significant portion
is associated with the use of medical devices, with 80% of these infections being caused by a bacterial
biofilm. The insertion of a foreign material usually elicits inflammation, which can result in hampered
antimicrobial capacity of the host immunity due to the effort of immune cells being directed to
degrade the material. The ineffective clearance by immune cells is a perfect opportunity for bacteria
to attach and form a biofilm. In this study, we analyzed the antibiofilm capacity of three naturally
derived biofilm inhibitors when combined with immune cells in order to assess their applicability
in implantable titanium devices and low-density polyethylene (LDPE) endotracheal tubes. To this
end, we used a system based on the coculture of HL-60 cells differentiated into polymorphonuclear
leukocytes (PMNs) and Staphylococcus aureus (laboratory and clinical strains) on titanium, as well as
LDPE surfaces. Out of the three inhibitors, the one coded DHA1 showed the highest potential to be
incorporated into implantable devices, as it displayed a combined activity with the immune cells,
preventing bacterial attachment on the titanium and LDPE. The other two inhibitors seemed to also
be good candidates for incorporation into LDPE endotracheal tubes.
Keywords: Staphylococcus aureus; biomaterials; medical devices; HL-60 cells; PMNs; biofilm;
endotracheal tube; titanium; implantable devices; nosocomial diseases
1. Introduction
Over 2.6 million new cases of healthcare-associated infections are annually reported just in
the European Union [1], and over 33,000 result in death [2] due to the increasing number of
antimicrobial-resistance cases [3]. At least 25% of these infections are associated with the use of
medical devices, and 80% of them are estimated to be caused by bacterial biofilms [4,5]. Biofilms are
defined as a community of microorganisms encased within a self-produced matrix that adheres to
biological or nonbiological surfaces [6,7]. They are currently regarded as the most important nonspecific
mechanism of antimicrobial resistance [8,9].
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During the worldwide crisis of SARS-CoV-2, as well as in many other pathological conditions,
mechanical ventilation is used to assist or replace spontaneous breathing as a life-saving procedure
in intensive care. However, the use of endotracheal intubation also poses major risks in prolonged
ventilation. The endotracheal tube provides an ideal opportunity for bacteria to form biofilms on
both the outer and luminal surface of the tube, increasing the risk of pulmonary infection by 6 to
10 times [10–12], with Staphylococcus spp. and Pseudomonas aeruginosa among the most frequent
colonizing agents [13]. Colonization by microorganisms and the subsequent formation of a biofilm
can happen within hours [13], but these kinds of devices are relatively easy to replace. On the other
hand, infection of orthopedic implants is particularly problematic, as these devices remain in the
body, often causing chronic and/or recurring infections mediated by biofilms. These infections also
frequently require removal of the infected implant, thereby causing implant failure [14–16]. Given the
rising number of implantations, the absolute number of complications is inevitably increasing at the
same pace, causing not only distress for the patients but also an increasing economic burden [15,16].
The most common causative agents of infection in orthopedic implants are Gram-positive cocci of
the genus Staphylococcus, e.g., Staphylococcus aureus and Staphylococcus epidermidis [17]. In the absence
of a foreign body, contaminations caused by these opportunistic pathogens are usually cleared by
the immune system. In contrast, the placement of an implant per se represents a risk factor for
the development of a chronic infection. This is due to the fact that the surgical procedure causes
tissue damage resulting in the local generation of damage-associated molecular patterns (DAMPs),
endogenous danger molecules that are released from damaged or dying cells and activate the innate
immune system by interacting with pattern recognition receptors (PRRs) [18]. This is sensed by
host neutrophils, which migrate to the injured tissue sites, activating defense mechanisms, such as
the generation of oxygen-derived and nitrogen-derived reactive species as well as phagocytosis,
to unsuccessfully attempt to clear the foreign material. These events lead to immune cell exhaustion
and death, and tissue damage caused by the triggered inflammation eventually leads to a niche
of immune suppression around the implant [19]. Under these specific conditions, the clearance of
planktonic bacteria by immune cells becomes impaired [14], which predisposes the implant to microbial
colonization and biofilm-mediated infection.
However, it is possible that not only host immune cells and bacterial cells can be present at
the moment of implantation, but also the cells of the tissue where the material is being implanted.
The “race for the surface” concept describes the competition between bacteria and the host cells of the
tissue where the device is implanted to colonize the surface of the material [20]. The rapid integration
of the material into the host tissue is a key component in the success of an implant, as the colonization
of the surface by the cells of the host not only ensures correct integration, but also prevents bacterial
colonization [21]. However, if bacterial adhesion occurs first, the host defense system is unable to
prevent the colonization and subsequent biofilm formation [22].
One of the current challenges to prevent and resolve biofilm-mediated infections is the limited
repertoire of compounds that are able to act on them at sufficiently low concentrations [23].
Because of this, there is intense ongoing research focused on the search for new biofilm
inhibitors by means of chemical screenings. However, for compounds to be truly effective
when used for the protection of biomaterials in translational applications, they must be tested
in meaningful experimental models. Based on this, we previously optimized an in vitro system
based on the coculture of SaOS-2, osteogenic cells, and S. aureus (laboratory and clinical strains)
on a titanium surface (Reigada; et al. [24]), and studied the effect of three naturally derived
biofilm inhibitors (Figure 1). Two of them were dehydroabietic acid (DHA) derivatives, namely,
N-(abiet-8,11,13-trien-18-oyl)cyclohexyl-L-alanine and N-(abiet-8,11,13-trien-18-oyl)-D-tryptophan,
coded DHA1 (Figure 1a) and DHA2 (Figure 1b), respectively. The third one was a flavan derivative,
6-chloro-4-(6-chloro-7-hydroxy-2,4,4-trimethylchroman-2-yl)benzene-1,3-diol, coded FLA1 (Figure 1c).
All of them were previously reported by our group and demonstrated to display activity in preventing
biofilm formation, as well as disrupting preformed S. aureus biofilms on 96-well plates [25,26], but the
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testing in the coculture model with osteogenic cells provided with new insights into their applicability
as part of anti-infective implantable devices.
The coculture model developed previously [24] involving SaOS-2 cells and S. aureus strains offered
an in vitro environment that was closer in terms of host–bacteria interactions and substrate materials to
the in vivo scenario of the implanted device. Moreover, in terms of antimicrobial evaluation, it provided
information not only regarding the antibiofilm activity but also about the effects on tissue integration.
However, this model did not assess the effect of the antimicrobials on immune cells. As mentioned
earlier, chronic inflammation not only lowers the antimicrobial efficacy, but also complicates the
integration of the implant material as a consequence of maintained inflammation and tissue damage.
Therefore, it is essential to assess the effect that antimicrobials might have in the presence of immune
cells, particularly for those intended to be used in medical devices. Endotracheal tubes significantly
differ from orthopedic implants in material, function, and implantation procedure, but they both cause
impairment of the host immune antimicrobial capacity.
Because of this, in this contribution, we move one step forward toward emulating in vivo
conditions encountered by medical devices in an in vitro setting. In this case, we introduce immune
cells, specifically neutrophils, in a coculture model with bacterial cells. Neutrophils were selected as
immune cells as they are the first cell types to migrate toward damaged tissue cells [27]. Our aim
was to develop cocultures of S. aureus and differentiated HL-60 cells, grown on titanium coupons
or low-density polyethylene (LDPE) tubes, to simulate biofilm formation on orthopedic implants or
endotracheal tubes, respectively. As a proof-of-concept, we also study the possible antimicrobial effects
of naturally derived antibiofilm inhibitors DHA1, DHA2, and FLA1, and their possible applicability
as part of medical devices.
2. Materials and Methods
2.1. Compounds
The dehydroabietic acid derivatives coded DHA1 and DHA2 (previously coded 11 and 9b,
respectively) were synthesized according to [25]. Their spectral data were identical to those reported
in [28]. The flavan derivative coded FLA1 (previously coded 291 in [26]), was purchased from TimTec
(product code: ST075672, www.timtec.net). These compounds were selected given their low minimum
inhibitory concentrations (MICs) and the low concentrations needed in order to prevent S. aureus
biofilm formation (Table S1). The control antibiotic rifampicin was purchased from Sigma-Aldrich
(CAS number 13292-46-1) and coded RIF. Molecular structures are shown in Figure 1.
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2.2. Bacterial Strains
Bacterial studies were performed using the laboratory strain S. aureus ATCC 25923 (American Type
Culture Collection, Manassas, VA, USA) and one clinical strain isolated from hip prostheses and
osteosynthesis implants at the Hospital Fundación Jiménez Díaz (Madrid, Spain) [29] (coded S. aureus P2).
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2.3. HL-60 Cell Culture and Differentiation
HL-60 (ATCC CCL-240) cells were grown and maintained in Roswell Park Memorial Institute
(RPMI) 1640 Medium (R8758, Sigma Aldrich, St. Louis, MO, USA), supplemented with 20% (v/v)
heat-inactivated fetal bovine serum (FBS) (Sigma Aldrich, St. Louis, MO, USA) and 1% (v/v)
penicillin/streptomycin (Sigma Aldrich, St. Louis, MO, USA). Cells were maintained in suspension at a
concentration between 105–106 cells/mL in 72 cm2 culture flasks (VWR, Radnor, PA, USA) at 37 ◦C in 5%
CO2 in a humidified incubator. N,N–Dimethylformamide (DMF)(Sigma Aldrich, St. Louis, MO, USA)
was utilized in order to differentiate the cells into polymorphonuclear-like cells [30]. In order to carry
out the differentiation, cells were cultured for 6 days in the maintenance medium at a concentration of
100 mM DMF. The success of the differentiation was assessed visually after Giemsa staining using a
Leica DMLS microscope (Leica, Wetzlar, Germany). Differentiated cells were neutrophil-like, with a
multilobar nucleus and a fairly clear cytoplasm.
2.4. Biofilm Prevention Efficacy of Differentiated HL-60 Cells against Different Bacterial Concentrations of
S. aureus ATCC 25923
2.4.1. Bacterial Inoculum Preparation
Pure colonies (2–3) of S. aureus ATCC 25923 were added to 5 mL of tryptic soy broth (TSB, Neogen®,
Lansing, MI, USA) and incubated overnight at 37 ◦C, 120 rpm. After incubation, 10 µL of the preculture
was added to 5 mL fresh TSB and incubated for 3–4 h (37 ◦C, 120 rpm), in order to obtain a midlogarithmic
growth phase of bacteria. Bacterial cultures were washed twice with sterile phosphate-buffered saline
(PBS; 140 mM NaCl, pH 7.4) and the concentration was adjusted to 2 × 108 in RPMI 1640 based on the
optical density of the suspension at 600 nm. From this stock, serial dilutions were made in RPMI 1640
between 2 × 108 and 2 × 102 CFU/mL.
2.4.2. Immune Cell (HL-60) Preparation
Twenty-four hours prior to starting the experiments, the media of the differentiated HL-60 cells
were refreshed with nonsupplemented RPMI 1640 in order to remove possible traces of antibiotics
from the maintenance media. Differentiated HL-60 cells (after 6 days exposure to a concentration
of 100 mM DMF) were counted with a Countess™ II automated cell counter (Thermo Scientific,
Waltham, MA, USA) and adjusted to a concentration of 2 × 105 cells/mL. In order to test the influence
of activating the cells with phorbol 12-myristate 13-acetate (PMA) (Sigma Aldrich, St. Louis, MO, USA)
on the antimicrobial capacity, half of the suspension of differentiated HL-60 cells was incubated for
20 min in RPMI 1640 supplemented with 25 nM PMA. PMA-activated and nonactivated HL-60 cells
were separately added (100 µL) to flat-bottomed, 96-well microplates (Nunclon ∆ surface, Nunc,
Roskilde, Denmark).
2.4.3. Coculture of S. aureus ATCC 25923 and HL-60 Cells
S. aureus ATCC 25923 suspensions at the different concentrations (100 µL) were added to the wells
of the 96-well microplate already containing 100 µL of one of the two different HL-60 cell suspensions
(activated or nonactivated). In the bacterial control wells, 100 µL of the S. aureus ATCC 25923 suspension
at different concentrations were added to wells containing 100 µL of RPMI 1640 alone. The wells
corresponding to the HL-60 cell control consisting of a suspension of HL-60 cells at a concentration
105 cells/mL in RPMI 1640 were used to observe the cell morphology after 18 h of incubation, but no
quantitative viability test was carried out. The 96-well microplates were incubated for 18 h at 37 ◦C
and 5% CO2 in a humidified incubator.
2.4.4. Biofilm Quantification in 96-Well Microplates
After S. aureus ATCC 25923 biofilms were grown, the media were carefully removed and each
well was washed twice with 125 µL sterile PBS, followed by the addition of 150 µL of TSB. Each 96-well
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microplate was closed with a plastic seal and parafilm and placed in a plastic bag, which was sealed
with heat in order to prevent leakage. The plate was sonicated for 10 min at 35 kHz in an Ultrasonic
Cleaner 3800 water bath sonicator (Branson Ultrasonics, Danbury, CT, USA) at 25 ◦C. This procedure
did not affect the viability of the staphylococci (Figure S1).
S. aureus ATCC 25923 was then resuspended in RPMI 1640 using 3 pipetting cycles (up/down).
Samples (10 µL) from each tested condition were transfer to 90 µL of TSB and serial dilutions were
made from 10−1 up to 10−7. Aliquots (10 µL) of all dilutions were transferred to sheep blood agar plates
(Amsterdam UMC, Amsterdam, The Netherlands) and incubated at 37 ◦C overnight. Viable plate
colonies were counted the next day.
2.5. Influence of Opsonizing S. aureus ATCC 25923 on the Efficacy of HL-60 Cells in Preventing Bacterial
Attachment on Titanium Coupons
S. aureus ATCC 25923 suspensions were prepared as described in Section 2.4.1. The inoculum was
adjusted to 2 × 107 CFU/mL and opsonized using 50% (v/v) pooled human serum in PBS (pooled from
15 healthy blood donors) by incubating at 37 ◦C for 30 min with gentle agitation, washing twice with
PBS, and resuspending in RPMI 1640 [31]. As a control, a nonopsonized suspension of S. aureus
ATCC 25923 was used. The two different suspensions (opsonized and nonopsonized), were then
added to sterilized titanium coupons (0.4 cm height, 1.27 cm diameter, BioSurface Technologies Corp.,
Bozeman, MT, USA).
On the other hand, HL-60 cells were prepared as described in Section 2.4.2 and added to the
titanium coupons, to which the bacterial suspension was previously added. The final volume covering
each coupon was 1 mL, made up of 500 µL of a suspension of 2 × 107 CFU/mL S. aureus ATCC 25923,
and 500 µL of a suspension of 2 × 105 HL-60 cells/mL in RPMI 1640.
2.6. Effect of the Antimicrobial Compounds on the Prevention of S. aureus ATCC 25923 and S. aureus P2
Adhesion in Coculture with Differentiated HL-60 Cells on Titanium Coupons
2.6.1. Culture of Staphylococci and HL-60 Cells
Bacterial inocula of S. aureus ATCC 25923 and S. aureus P2 were prepared as described in
Section 2.4.1. The concentration was adjusted to 2 × 107 CFU/mL in RPMI 1640. For the differentiated
HL-60 cells, the media were refreshed with RPMI 1640 24 h before the experiments started in order
to remove possible traces of antibiotics from the maintenance media. On the day of the experiment,
cells were counted with a Countess™ II automated cell counter (Thermo Scientific, Waltham, MA, USA)
and adjusted to a concentration of 2 × 105 cells/mL in RPMI 1640. Each suspension (bacterial and
HL-60 cells suspensions, 500 µL of each) was added to sterilized titanium coupons that were inserted
in the different wells of a 24-well plate (Nunclon ∆ surface, Nunc, Roskilde, Denmark) and to which
the different tested compounds or the control antibiotics were added at a concentration of 50 µM
(0.25% DMSO).
The 24-well plates containing the titanium coupons were maintained in cocultures with a solution
containing 107 CFU of S. aureus ATCC 25923 or S. aureus P2 and 105 HL-60 cells in a total volume of
1 mL of RPMI 1640 for 24 h. Titanium coupons with added RIF (50 µM, 0.25% DMSO) were used as
positive antibiotic controls. As coculture controls, titanium coupons without the addition of the tested
antimicrobial compounds or control antibiotics were exposed simultaneously to both cellular systems
(S. aureus and HL-60 cells) at the concentrations previously described. In addition, bacterial controls
(exposed or not to the antimicrobial compounds in the absence of differentiated HL-60 cells) were
also included.
2.6.2. Bacterial Adherence on Titanium Coupons
Titanium coupons were gently washed with TSB to remove remaining adhering planktonic cells
and transferred to Falcon tubes containing 1 mL of 0.5% (w/v) Tween® 20-TSB solution. Next, the tubes
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were sonicated in an Ultrasonic Cleaner 3800 water bath sonicator (Branson Ultrasonics, Danbury,
CT, USA) at 25 ◦C for 5 min at 35 kHz. The tubes were vortexed for 20 s prior to and after the sonication
step. Serial dilutions of the resulting bacterial suspensions were made from 10-1 up to 10−7 and plated
on tryptic soy agar (Neogen®, Lansing, MI, USA) plates.
2.7. Effect of the Antimicrobial Compounds on the Prevention of S. aureus ATCC 25923 Adhesion in Coculture
with Differentiated HL-60 Cells on LDPE Tubes
The assay was carried out as described in Section 2.6 but instead of titanium coupons the materials
added to the 24-well plates were 1 cm long sections of a sterilized fine bore LDPE tubing (Smiths Medical
ASD, Minneapolis, MN, USA).
2.8. Scanning Electron Microscopy (SEM)
In order to visualize the effect of the antimicrobial compounds on the prevention of S. aureus
ATCC 25923 adhesion in coculture with immune cells on titanium coupons, S. aureus ATCC 25923 was
cocultured with differentiated HL-60 cells on titanium coupons, as described in Section 2.6. Prior to SEM,
samples were fixed in 4% (v/v) paraformaldehyde and 1% (v/v) glutaraldehyde (Merck, Kenilworth,
NJ, USA) overnight at room temperature. Samples were rinsed twice with distilled water, with the
duration of each cycle being 10 min. The dehydration procedure consisted of 2 cycles of incubation for
15 min in 50% (v/v) ethanol, 2 cycles of incubation for 20 min in 70% (v/v) ethanol, 2 cycles of incubation
for 30 min in 80% (v/v) ethanol, 2 cycles of incubation for 30 min in 90% (v/v) ethanol, and 2 cycles of
incubation for 30 min in 100% (v/v) ethanol. In order to reduce the sample surface tension, samples were
immersed in hexamethyldisilazane (Polysciences Inc., Warrington, FL, USA) overnight and air-dried.
Before imaging, samples were mounted on aluminum SEM stubs and sputter-coated with a 4 nm
platinum–palladium layer using a Leica EM ACE600 sputter coater (Leica Microsystems, Wetzlar,
Germany). Images were acquired at 2 kV using a Zeiss Sigma 300 SEM (Zeiss, Oberkochen, Germany)
at the Electron Microscopy Center Amsterdam (Amsterdam UMC).
Of each coupon, 8–10 fields were viewed and photographed at magnifications of 250×, 500×,
1000×, and 3000×. Representative images are shown in the results.
2.9. Statistical Analysis
The quantitative data are reported as the mean and standard deviation (SD) of at least three
independent experiments. Data were analyzed using GraphPad Prism 8 for Windows. For statistical
comparisons, Tukey’s multiple comparison test and Welch’s unpaired t-test were applied, and p < 0.05
was always considered as statistically significant.
3. Results
3.1. Effect of PMA Activation of Differentiated HL-60 Cells on Prevention of S. aureus ATCC 25923
Biofilm Formation
Before performing the experiments with the titanium coupons and the antimicrobial compounds,
the initial concentration of S. aureus ATCC 25923 was determined where the bacteria were able to form
a biofilm in absence of the HL-60 cells, but were prevented from forming a biofilm when cocultured
with 105 HL-60 cells. At the same time, it was assessed whether the activation of the HL-60 cells
with PMA enhanced their bacterial clearance capability (Figure 2). At an initial S. aureus ATCC 25923
concentration of 108 CFU/mL, HL-60 cells did not significantly affect the bacterial attachment in 96-well
microplates. A reduction on the adhered S. aureus ATCC 25923 viable cell counts was observed at an
S. aureus ATCC 25923 concentration of 107 CFU/mL and below (p < 0.001 in all cases when comparing
the bacterial control with bacteria cocultured with HL-60 cells, and p = 0.001 for cells activated with
PMA and a starting inoculum of 103 CFU/Ml), with the exception of the lowest bacterial concentration
tested, i.e., 102 CFU/mL, where no difference was found. Both PMA-activated and nonactivated
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HL-60 cells (gray and green columns, respectively) showed similarly reduced numbers of adherent
S. aureus ATCC 25923 viable cell counts at 24 h, so it was concluded that activation with PMA does not
significantly enhance S. aureus ATCC 25923 clearance.
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Figure 2. iable counts of 24-hour-old biofilms formed by different concentrations of S. aureus
ATCC 25923 cocultured with HL-60 cells on 96-well microplates. Black colu ns represent the bacterial
control (viable attached cells in the absence of HL-60 cells). Green columns show the coculture of S. aureus
ATCC 25923 with HL-60 cells differentiated with N,N-dimethylformamide (DMF). Gray columns show
the coculture of S. aureus ATCC 25923 with HL-60 cells differentiated with DMF and activated with
phorbol 12-myristate 13-acetate (PMA). Values are means and SD of three independent experiments
(*** p < 0.001; ** p < 0.01).
Based upon these results, the optimal initial S. aureus ATCC 25923 concentration was found to
be 107 CFU/mL, which was then selected for the rest of the experiments. Since PMA activation of
the HL-60 cells did not influence their phagocytic activity, no PMA stimulation was performed in
subsequent experiments.
3.2. Influence of Opsonizing S. aureus ATCC 25923 on the Efficacy of HL-60 Cells in Preventing Bacterial
Attachment on Titanium Coupons
One of the most relevant mechanisms of the host defense against Staphylococcus spp. is phagocytosis.
Given that opsonization of S. aureus is important for neutrophils to be able to clear planktonic
S. aureus [32], the phagocytic efficacy of HL-60 cells, as well as the impact of opsonization of
S. aureus ATCC 25923, in preventing S. aureus ATCC 25923 biofilm formation on titanium coupons
was simultaneously explored (Figure 3). The left part of Figure 3 shows how the preventive
capability of HL-60 cells was preserved when tested on titanium surfaces (p < 0.001, when comparing
S. aureus + HL-60 (gray column) with the bacterial control (black column)). This bacterial clearance
activity was also observed when S. aureus ATCC 25923 was opsonized (p = 0.007), but no significant
differences were found when comparing the effects of the HL-60 cells on opsonized versus nonopsonized
S. aureus ATCC 25923 (p = 0.260). The antibacterial effects of PMA-activated HL-60 cells against
opsonized S. aureus ATCC 25923 was additionally explored, but no differences were found with the
antimicrobial activity of nonactivated HL-60 against nonopsonized S. aureus ATCC 25923 (Figure S2).
Because opsonization did not enhance the bacterial clearance capacity of HL-60, the use of opsonized
S. aureus during the rest of the experiments was decided against.
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Figure 3. Viable counts of adhered opsonized and nonopsonized S. aureus ATCC 25923 on titanium
coupons after coculture with HL-60 cells for 24 h. The left h f the graph includes the nonopsonized
S. aureus ATCC 25923 biofilm for ation, i absence (black c l n) or coc ltured with HL-60 cells
(green column). The right half includes the opsonized S. aureus ATCC 25923 biofilm formation,
in absence (white/black column) or cocultured with HL-60 cells (green/black column). “*” indicates
statistical differences with the nonopsonized S. aureus ATCC 25923 in monoculture, while “#” represents
statistical differences with the opsonized S. aureus ATCC 25923 in monoculture with Welch’s unpaired
t-test (*** p < 0.001; ## p < 0.01). Values are means and SD of three independent experiments.
3.3. Effect of the Antimicrobial Compounds on the Prevention of S. aureus Adhesion in Coculture with
Differentiated HL-60 Cells on Titanium Coupons
The effects of the three biofilm nhibitors DHA1, DHA2, and FLA1 and one co tibiotic, RIF,
on the prevention of S. aureus attachment on titanium coupons were investigated using two strains,
the laboratory strain ATCC 25923 (Figure 4a) and the clinical isolate P2 (Figure 4b), either in the absence
(gray bars) or presence of HL-60 cells (green bars). In the absence of HL-60 cells, all of the tested
antimicrobial compounds, as well as the control antibiotic, significantly reduced the attachment of
S. aureus ATCC 25923 (p < 0.001, p = 0.040, p < 0.001, and p < 0.001, for DHA1, DHA2, FLA1, and RIF
versus the cont l, respectively). In the case of t e clinical st ain (Figure 4b), ll the antimicrobial
compounds, except DHA2, also showed antimicrobial activity in the absence of HL-60 cells (p = 0.0067,
p < 0.001, and p = 0.0087 versus control for DHA1, FLA1, and RIF, respectively).Microorganisms 2020, 8, x FOR PEER REVIEW 9 of 15 
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in the HL-60 cells + S. aureus ATCC 25923 section of Figure 4, and p < 0.001 when comparing the DHA1
gray column with the DHA1 green column). The same tendency was observed for DHA2, but no
statistical differences were found when comparing this to the control (dark green control: HL-60 cells +
S. aureus ATCC 25923 section of Figure 4). Despite the fact that FLA1 and the model antibiotic (RIF)
successfully prevented the adhesion of S. aureus ATCC 25923, they did not cause a further increase in
the bacterial clearance activity of the HL-60 cells. In contrast, the mere presence of HL-60 cells did
not result in a significant reduction of S. aureus P2 attachment (Figure 4b), since no differences were
found between the S. aureus P2 control in monoculture and in coculture with HL-60 cells. In this case,
no differences were found between the antibacterial effects of the compounds in monoculture when
compared with the same treatment in coculture with HL-60 cells (DHA1, DHA2, FLA1, and RIF gray
columns versus their corresponding green columns).
Using SEM imaging, it was visually confirmed that DHA1 reduced the number of S. aureus
ATCC 25923 adherent to the titanium surface (Figure 5). In fact, almost no cocci were observed on the
DHA1-treated titanium across the entire coupon. In addition, the presence of HL-60 cells also reduced
the bacterial attachment, which was further enhanced by the treatment of DHA1. Adherent HL-60
cells were observed, as seen in the last row of images.
BACTERIAL CONTROL: S. aureus ATCC 25923 
S. aureus ATCC 25923 + DHA1 (50 µm)
S. aureus ATCC 25923 + HL-60 cells + DHA1 (50 µm)
CO-CULTURE CONTROL: S. aureus ATCC 25923 + HL-60 cells
Figure 5. Representative images acquired by SEM. From left to right the same section of the titanium
coupon is shown with different magnification, 500, 1000 and 3000×. Upper row of images, bacterial
control, i.e., coupons incubated with S. aureus ATCC 25923 only. Second row, titanium coupons
incubated with S. aureus ATCC 25923 and treated with DHA1. Third row, cocultured control, titanium
coupons incubated with S. aureus ATCC 25923 and HL-60 cells simultaneously. Fourth row, titanium
coupons cocultured with S. aureus ATCC 25923 and HL-60 and treated with DHA1.
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3.4. Effect of the Antimicrobial Compounds on the Prevention of S. aureus ATCC 25923 Adhesion in Coculture
with Differentiated HL-60 Cells on LDPE tubes
The adhesive capacity of S. aureus, as well as the antimicrobial effect of different compounds,
is known to significantly differ depending on the material [33]. For this reason, the applicability of the
compounds as part of endotracheal tubes was tested on a clinically relevant material, LDPE. Figure 6
shows the effects of the tested compounds and the control antibiotic (RIF) on the prevention of S. aureus
ATCC 25923 attachment on LDPE tubes. The left part of the figure shows that all the antimicrobial
compounds significantly reduced the numbers of attached viable S. aureus ATCC 25923 cells, in the
absence of HL-60 (p < 0.001, p = 0.0035, p < 0.001, and p < 0.001, when comparing, respectively, DHA1,
DHA2, FLA1, and RIF with the control). Adding HL-60 cells resulted in significant prevention of
S. aureus ATCC 25923 attachment to LDPE tubes (p < 0.001 when comparing the coculture control
(dark green column) with the bacterial control (black column)). In this case, all the antimicrobial
compounds looked to be able to further potentiate this bacterial clearance capability (p < 0.001, p = 0.023,
p = 0.002, and p < 0.001, when comparing, respectively, DHA1, DHA2, FLA1, and RIF light green
columns with the control dark green column). However, similarly to what was observed on the
titanium model, it was only the DHA1 treatment that further potentiated the action of HL-60 cells
against S. aureus ATCC 25923 (p = 0.015, when comparing the DHA1 gray column with the DHA1
green column). No differences were found between the viable cells (CFU/mL) attached on the LDPE
exposed to S. aureus ATCC 25923 and treated with DHA2, FLA1, and RIF in monoculture and those
exposed to both S. aureus ATCC 25923 and HL-60 with the same treatments (gray columns versus
green columns). Full bacterial clearance was detected in LDPE tubes in the presence of DHA1 and RIF
(i.e., no viable bacterial counts measured), where cocultures of S. aureus ATCC 25923 with differentiated
HL-60 cells were formed. These findings further highlight the relevance of DHA1 as an antimicrobial
candidate for incorporation into medical devices.
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Figure 6. Viable counts of adhered S. aureus ATCC 25923 on LDPE tubes exposed to different
antimicrobial compounds (tested at 50 µM) after 24 h of incubation. The gray bars show the attached
viable bacteria when exposed just to the antimicrobial compounds, while the green bars show the
results when S. aureus strains were cocultured with HL-60 cells. “*” indicates statistical differences with
the control in monoculture, while “#” represents statistical differences with the control in cocultured
controls with Welch’s unpaired t-test (** p < 0.01; *** p < 0.001)/(# p < 0.05; ## p < 0.01; ### p < 0.001).
Values are means and SD of three independent experiments.
4. Discussion
In this study, we explored the potential of incorporation of three previously identified naturally
derived biofilm inhibitors into medical devices, particularly for titanium implantable devices and
LDPE endotracheal tubes. From the three tested antimicrobial compounds, in line with previous
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findings [24], DHA1 appeared to be the best candidate for incorporation as part of implantable medical
devices. All of the compounds proved to be interesting candidates to include into anti-infective
endotracheal tubes, but it was DHA1 that again showed itself to be the most promising candidate, as it
was the only one that significantly increased the bacterial clearance capacity of HL-60 cells against
S. aureus ATCC 25923.
For compounds to be truly effective when used for protection of biomaterials in translational
applications, they must be tested in meaningful experimental models. The insertion of any device
provokes an acute inflammatory response that may cause ineffectiveness of innate immune cells such
as neutrophils in cleaning planktonic bacteria, since these cells are directed to degrade the material.
For this reason, it is vitally important to study the effects of antimicrobial compounds on neutrophils
to assess their suitability as part of medical devices.
Before this investigation, no published reports existed on the effect of the two DHA derivatives
(DHA1 and DHA2) on neutrophils, however, the parent compound (dehydroabietic acid, DHA)
was previously reported to have slight toxicity toward this cell type [34]. This prior knowledge further
justified the need for an assessment of the effects of DHA1 and DHA2 on the bacterial clearance
capacity of neutrophils. Similarly, no data existed on effects of FLA1 on neutrophils, but other flavan
derivatives were studied. Out of 10 different flavan-3-ol derivatives tested on human neutrophils,
only two presented a slight toxic effect toward the neutrophils, but all of them reduced reactive oxygen
species (ROS) and interleukin-8 production [35]. On the other hand, flavan-3-ol derivatives extracted
from Bistorta officinalis (Delarbre) were reported to inhibit tumor necrosis factor-α (TNF-α) release from
neutrophils [36]. These earlier findings were promising in terms of applying the flavan derivative FLA1
as part of medical devices, since its antimicrobial capacity in combination with its anti-inflammatory
effects could result in prevention of infection while providing ideal cues toward material integration
and resolution of inflammation.
In this study, we utilized HL-60 cells differentiated to polymorphonuclear-like cells in order
to study the effects of the antimicrobial compounds in the presence of neutrophils. Alternatively,
freshly extracted neutrophils could also have been used, but in such case differences would be
encountered between individual donors in terms of reproducibility, the total number of cells that
can be harvested, their short lifespan, or the disturbances in their physiology due to isolation
procedures [37,38].
The three tested antimicrobial compounds and the control antibiotic (RIF) reduced S. aureus
ATCC 25923 adhesion to titanium in the absence of HL-60 at the tested concentration of 50 µM. In the
case of the clinical S. aureus strain, all compounds, except DHA2, significantly reduced S. aureus
P2 biofilm formation on titanium in the absence of HL-60. The prevention of biofilm formation by
DHA1 and FLA1 was as expected, as the compounds were used at concentrations higher than their
MIC values [25,26]. Compound DHA2 showed some prevention activity, despite being tested at a
concentration slightly below its MIC (i.e., 60 µM) [26]. As with most antimicrobials, cytotoxicity
is a concern, and DHA2 was shown to reduce viability of HL cells (originating from the human
respiratory tract) at a concentration of 100 µM [25].
The mere presence of HL-60 cells significantly reduced the bacterial attachment of S. aureus
ATCC 25923. In contrast, this effect was not observed for the clinical S. aureus strain P2. This was
also observed in our previous study, with the results obtained with the laboratory strain S. aureus
ATCC 25923 significantly differing from the ones obtained with S. aureus P2 under the same experimental
conditions. The latter has a key relevance in assessing the applicability of biofilm inhibitors as part of
titanium implantable devices, as it was isolated from patients with orthopedic device-related infections.
For this reason, the additional measurement of the preventive capacity of the biofilm inhibitors against
the clinical S. aureus P2 strain is of great relevance.
Compound DHA1 was shown to further potentiate S. aureus ATCC 25923 clearance caused by
HL-60, and this effect was further confirmed by SEM. This compound also managed to effectively
prevent the adherence of the clinical strain (S. aureus P2), but in this case it was difficult to establish
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if the reduction in bacterial attachment caused by DHA1 (as well as FLA1 and RIF) was due to a
combined antimicrobial effect with the HL-60 cells or if it was due to their intrinsic antimicrobial
capacity, as their effects in monoculture were equal to those observed in coculture with the HL-60 cells.
These results emphasized the importance of not limiting the in vitro experimentation to laboratory
strains, especially in cases aimed at finding compounds effective against medical device-associated
infections, as the results obtained with laboratory strains may overestimate the efficacy of the compound.
These results demonstrate that DHA1 seems to further increase S. aureus ATCC 25923 clearance by
HL-60, while none of the other compounds negatively affect the antimicrobial effect of these immune
cells. This is also of high relevance, as adverse effects on the immune response could be detrimental,
and even increase the risk of infection. As an example, Croes et al. [39] biofunctionalized the surface of
titanium implants with chitosan-based coatings that were incorporated with different concentrations of
silver nanoparticles. Despite the good antimicrobial results obtained in the in vitro tests, these coatings
did not demonstrate antibacterial effects in vivo. Due to the toxicity of the silver nanoparticles on the
immune cells, these coatings aggravated infection-mediated bone remodeling, including increased
osteoclast formation and inflammation-induced new bone formation.
Similar results were obtained in LDPE tubes, with the bacterial clearance capacity of the HL-60 cells
against S. aureus ATCC 25923 also observed, and DHA1 further potentiated this activity. The prevention
of S. aureus adherence on the surface of endotracheal tubes may have potential to significantly reduce
the rates of ventilator-associated pneumonia caused by these bacteria [40]. Additionally, by preventing
the attachment of S. aureus, the attachment of P. aeruginosa may also be hampered, as several
infection models demonstrated how early colonization by S. aureus facilitated subsequent P. aeruginosa
colonization [41,42]. The development of a dual-species biofilm is expected to not only strongly worsen
the pathology but significantly complicate the treatment [43].
In this study, and in concordance with our previous findings, DHA1 was identified as the best
candidate to be incorporated into implantable devices. This is because, in addition to its intrinsic
antibiofilm capacity against both laboratory and clinical strains of S. aureus, it also seems to be able
to enhance S. aureus ATCC 25923 clearance by HL-60 cells. Further mechanistic studies should be
performed in order to elucidate if DHA1 has a direct effect on the antimicrobial activity of PMNs. In the
near future, we plan to assess the effects of DHA1 on phagocytosis, ROS production, and formation of
neutrophil extracellular traps (NETs).
Given the promising results that DHA1 showed, both in our previous publications and in
the current one, this biofilm inhibitor is involved in plans to be integrated as part of a titanium
coating by means of 3D printing, with the coating formulation consisting of DHA1-loaded
poly(lactic-co-glycolic acid) micro particles that suspended in a gelatine–methacrylate gel inkjet-printed
onto titanium coupons [44]. The printing procedure is already validated and the prototype materials
are currently being tested. In the case of endotracheal tubes, our current results suggest that all of
the tested antimicrobial compounds would be beneficial for the prevention of S. aureus adhesion and
subsequent biofilm formation, but DHA1 appears to be the best candidate.
To the best of our knowledge, this is one of the first studies showing a positive effect of novel
antimicrobials on the antibiofilm-clearing capacity of immune cells. This is of particular relevance
because it does not only provide new alternatives to fight against the immense burden of bacterial
biofilms, but it also sets the basis for a new in vitro system to accelerate the drug discovery process,
thereby enabling better selection of antimicrobial incorporation into medical devices.
5. Conclusions
We showed the suitability of a coculture of S. aureus and differentiated HL-60 cells as an in vitro
assay to assess the applicability of antimicrobial compounds for the protection of medical devices.
As a proof-of-concept, we tested three antimicrobials, concluding that the DHA derivative DHA1
is the best candidate for incorporation into implantable devices, as it does not only prevent biofilm
formation on titanium but also seems to enhance the antibacterial capability of immune cells. On the
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other hand, according to our results, all of the antimicrobial compounds studied here, i.e., the two
DHA derivatives, DHA1 and DHA2, and the flavan derivative, FLA1, can tentatively be regarded as
promising candidates to form part of anti-infective endotracheal tubes.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/2076-2607/8/11/1757/
s1.
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